Turner syndrome, which can be defined as the loss or abnormality of the second X chromosome in a phenotypic female Not Applicable Turner's syndrome
Conditions
Interventions
Girls with Turner syndrome receiving a standard dose of growth hormone therapy are randomised to receive oxandrolone (0.05mg/kg/day
max. dose 2.5mg/day) or placebo from 9 years until final height. Participants are further randomised at 12 years of age to either begin pubertal induction (Ethinylestradiol Yr 1: 2mcg daily/Yr 2: 4mc
Sponsors
NHS Greater Glasgow & Clyde (UK)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Girls with Turner syndrome, confirmed by karyotype 2. Age 7 - 13 years 3. Naive to growth hormone therapy or previous treatment within specified range (8.3-11.7mg/m2/week in 5-7 injections per week) 4. Naive to oxandrolone or oestrogen therapy 5. Open epiphyses 6. Free from major systemic illness likely to impact growth
Exclusion criteria
Exclusion criteria: 1. Age 0 - 6 years or 14+ years 2. Fused epiphyses 3. Chronic illness likely to impact growth 4. Social or psychological difficulties thought likely to result in serious impairment of concordance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Final adult height (cm), defined as height velocity <1 cm/year and bone age =15.5 years. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Maximum height, i.e. the most recently available height 2. Age of attaining final height 3. Three summary growth parameters (size, tempo, velocity) | — |
Countries
United Kingdom
Outcome results
None listed